Historically, the potential role of PP2A in cancer was postulated when it was reported that okadaic acid, a potent inhibitor of the holoenzyme, had a drastic effect in tumor progression through B-catenin transcription and AKT activation [135]. The gene discussed is PTPA; the disease is cancer.